MedTrace Logo

Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA

NCT04462614 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-07-08

No results posted yet for this study

Summary

Use HeprAN ™ membrane (coated with heparin) should be allow the success of dialysis sessions, with adequate dialysis parameters, in patients treated by long-term anticoagulation with VKA, without addition of heparin perdialytic.

Less use of heparin (UFH or LMWH) during hemodialysis session should be allow a decrease of bleedings (moderate or major) and blood transfusions for hemodialysed patients with HeprAN ™ membrane and treated by long-term anticoagulation with VKA

Conditions

  • Chronic Hemolysis
  • VKA
  • Anticoagulants / Administration & Dosage
  • Coated Materials
  • Biocompatible
  • Heparin / Administration & Dosage
  • Membranes Artificial
  • Prospective Studies
  • Renal Dialysis / Methods
  • Renal Insufficiency / Therapy

Interventions

DRUG

Decrease per-dialytic heparin therapy

Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.

Sponsors & Collaborators

  • CHU de Reims

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2021-01-31
Completion
2021-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04462614 on ClinicalTrials.gov